:quality(75)/cdn.jwplayer.com/v2/media/A2nDYjO2/poster.jpg)
Píldora de la farmacéutica Pfizer contra la COVID-19 podría estar lista a fines del 2021
Esta píldora ha sido formulada para atacar la “espina dorsal” del virus del SARS-Cov-2.
- 27 de abril de 2021 05:26 p.m.
- Duración: 03:11
Esta píldora ha sido formulada para atacar la “espina dorsal” del virus del SARS-Cov-2.
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/VNKELAZWXBHNPDM337JKUASCAU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/7PVAK2KSTFHZLH6PZPL2HFEMKQ.png)
:quality(75)/cdn.jwplayer.com/v2/media/7xdUIehY/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/V6yMsk03/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/ybUFJmsY/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UX73NYMVGNGAHCG6TVRR5XHN7A.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/GWJC3MRSOJCW5JBSP7LXPNSTEM.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/NNVPBUEES5HITMQBXWL7ZV5OLA.png)
:quality(75)/cdn.jwplayer.com/v2/media/wSCZhTNm/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/dhXkTcsE/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/0VrIcTuT/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/3GS5IXLICBENBALWRSNYLVZIDU.jpg)